The immune network in thyroid cancer

References

• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx.doi.org/10.1172/JCI35180
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/35074122
   PubMed Web of Science ®Google Scholar
• Cunha LL, Marcello MA, Ward LS. The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocrine-related cancer 2014; 21:R85-R103; PMID:24302667; http://dx.doi.org/10.1530/ERC-13-0431
   PubMedGoogle Scholar
• Carling T, Udelsman R. Thyroid cancer. Ann Rev Med 2014; 65:125-37; PMID:24274180; http://dx.doi.org/10.1146/annurev-med-061512-105739
   PubMed Web of Science ®Google Scholar
• Hsiao SJ, Nikiforov YE. Molecular approaches to thyroid cancer diagnosis. Endocrine-related cancer 2014; 21:T301-13; PMID:24829266; http://dx.doi.org/10.1530/ERC-13-0165
   PubMedGoogle Scholar
• Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159:676-90; PMID:25417114; http://dx.doi.org/10.1016/j.cell.2014.09.050
   PubMed Web of Science ®Google Scholar
• Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39:1003-18; PMID:24332029; http://dx.doi.org/10.1016/j.immuni.2013.11.010
   PubMed Web of Science ®Google Scholar
• Weetman AP, Bennett GL, Wong WL. Thyroid follicular cells produce interleukin-8. J Clin Endocrinol Metab 1992; 75:328-30; PMID:1619027; http://dx.doi.org/10.1210/jcem.75.1.1619027\
   PubMed Web of Science ®Google Scholar
• Kammoun-Krichen M, Bougacha-Elleuch N, Mnif M, Bougacha F, Charffedine I, Rebuffat S, Rebai A, Glasson E, Abid M, Ayadi F et al. IL-1beta a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis. Eur Cytokine Netw 2012; 23:101-6; PMID:22995155; http://dx.doi.org/10.1684/ecn.2012.0312
   PubMed Web of Science ®Google Scholar
• Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Ann Rev Immunol 2013; 31:317-43; PMID:23298208; http://dx.doi.org/10.1146/annurev-immunol-032712-095906
   PubMed Web of Science ®Google Scholar
• Genovese A, Borgia G, Bjorck L, Petraroli A, de Paulis A, Piazza M, Marone G. Immunoglobulin superantigen protein L induces IL-4 and IL-13 secretion from human Fc epsilon RI+ cells through interaction with the kappa light chains of IgE. J Immunol 2003; 170:1854-61; PMID:12574351; http://dx.doi.org/10.4049/jimmunol.170.4.1854
   PubMed Web of Science ®Google Scholar
• Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013; 229:176-85; PMID:23096265; http://dx.doi.org/10.1002/path.4133
   PubMed Web of Science ®Google Scholar
• Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA, Fagin JA. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PloS one 2013; 8:e54302; PMID:23372702; http://dx.doi.org/10.1371/journal.pone.0054302
   Google Scholar
• Ameziane-El-Hassani R, Talbot M, de Souza Dos Santos MC, Al Ghuzlan A, Hartl D, Bidart JM, De Deken X, Miot F, Diallo I, de Vathaire F et al. NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc Natl Acad Sci U S A 2015; 112:5051-6; PMID:25848056; http://dx.doi.org/10.1073/pnas.1420707112
   PubMed Web of Science ®Google Scholar
• Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer letters 2015; 367:103-7; PMID:26188281; http://dx.doi.org/10.1016/j.canlet.2015.07.009
   PubMed Web of Science ®Google Scholar
• Li C, Li H, Jiang K, Li J, Gai X. TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-beta1 and IL-10 and tumor cells migration. Bio-medical materials and engineering 2014; 24:869-75; PMID:24211974; http://dx.doi.org/10.3233/BME-130879
   PubMed Web of Science ®Google Scholar
• Yu H, Huang X, Liu X, Jin H, Zhang G, Zhang Q, Yu J. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 2013; 44:172-81; PMID:23264145; http://dx.doi.org/10.1007/s12020-012-9853-2
   PubMed Web of Science ®Google Scholar
• Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesu G et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 2006; 66:1491-9; PMID:16452205; http://dx.doi.org/10.1158/0008-5472.CAN-05-2514
   PubMed Web of Science ®Google Scholar
• Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G, De Maria R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003; 63:6784-90; PMID:14583474
   PubMed Web of Science ®Google Scholar
• Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011; 127:701-21 e1-70; PMID:21377040; http://dx.doi.org/10.1016/j.jaci.2010.11.050
   PubMed Web of Science ®Google Scholar
• Shinohara S, Rothstein JL. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. Oncogene 2004; 23:7571-9; PMID:15326486; http://dx.doi.org/10.1038/sj.onc.1207964
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16:448-57; PMID:25898198; http://dx.doi.org/10.1038/ni.3153
   PubMed Web of Science ®Google Scholar
• Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, Rossi FW, Basolo F, Ugolini C, de Paulis A et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 2010; 29:6203-15; PMID:20729915; http://dx.doi.org/10.1038/onc.2010.348
   PubMed Web of Science ®Google Scholar
• Visciano C, Liotti F, Prevete N, Cali G, Franco R, Collina F, de Paulis A, Marone G, Santoro M, Melillo RM. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene 2015; 34:5175-86; PMID:25619830; http://dx.doi.org/10.1038/onc.2014.441
   PubMed Web of Science ®Google Scholar
• Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10:554-67; PMID:20616810; http://dx.doi.org/10.1038/nri2808
   PubMed Web of Science ®Google Scholar
• Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 2011; 30:3153-62; PMID:21383698; http://dx.doi.org/10.1038/onc.2011.44
   PubMed Web of Science ®Google Scholar
• Eloy C, Santos J, Cameselle-Teijeiro J, Soares P, Sobrinho-Simoes M. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch 2012; 460:587-600; PMID:22527019; http://dx.doi.org/10.1007/s00428-012-1234-y
   PubMed Web of Science ®Google Scholar
• Jiang G, Ma S, Wei Y, Wu Y, Yu X, Liu H. The prevalence and distribution of Th17 and Tc17 cells in patients with thyroid tumor. Immunology letters 2014; 162:68-73; PMID:25068436; http://dx.doi.org/10.1016/j.imlet.2014.07.005
   PubMed Web of Science ®Google Scholar
• Lee YC, Chung JH, Kim SK, Rhee SY, Chon S, Oh SJ, Hong IK, Eun YG. Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population. Cytokine 2015; 71:283-8; PMID:25484349; http://dx.doi.org/10.1016/j.cyto.2014.11.011
   PubMed Web of Science ®Google Scholar
• Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol 2015; 15:185-9; PMID:25677493; http://dx.doi.org/10.1038/nri3803
   PubMed Web of Science ®Google Scholar
• Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18:1248-53; PMID:22772464; http://dx.doi.org/10.1038/nm.2856
   PubMed Web of Science ®Google Scholar
• Xiao M, Hu S, Tang J, Zhang L, Jiang H. Interleukin (IL)-21 promoter polymorphism increases the risk of thyroid cancer in Chinese population. Gene 2014; 537:15-9; PMID:24389496; http://dx.doi.org/10.1016/j.gene.2013.12.050
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; http://dx.doi.org/10.1038/nri3845
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Mattei F, Gabriele L. Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. Front Immunol 2013; 4:483; PMID:24400008; http://dx.doi.org/10.3389/fimmu.2013.00483
   PubMed Web of Science ®Google Scholar
• Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 2014; 20:6034-44; PMID:25294906; http://dx.doi.org/10.1158/1078-0432.CCR-14-0879
   PubMed Web of Science ®Google Scholar
• Bosisio D, Salvi V, Gagliostro V, Sozzani S. Angiogenic and antiangiogenic chemokines. Chem Immunol Allergy 2014; 99:89-104; PMID:24217604; http://dx.doi.org/10.1159/000353317
   PubMedGoogle Scholar
• Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068-81; PMID:15761501; http://dx.doi.org/10.1172/JCI200522758
   PubMed Web of Science ®Google Scholar
• Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A 2005; 102:14825-30; PMID:16203990; http://dx.doi.org/10.1073/pnas.0503039102
   PubMed Web of Science ®Google Scholar
• Rotondi M, Coperchini F, Chiovato L. CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. Cytokine & growth factor reviews 2013; 24:539-46; PMID:24011840; http://dx.doi.org/10.1016/j.cytogfr.2013.08.001
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, Santarpia L, Basolo F, Ferrannini E, Miccoli P. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine 2012; 59:218-22; PMID:22633083; http://dx.doi.org/10.1016/j.cyto.2012.04.042
   PubMed Web of Science ®Google Scholar
• Rotondi M, Coperchini F, Pignatti P, Magri F, Chiovato L. Metformin reverts the secretion of CXCL8 induced by TNF-alpha in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. J Clin Endocrinol Metab 2015; 100:E427-32; PMID:25590211; http://dx.doi.org/10.1210/jc.2014-3045
   PubMedGoogle Scholar
• Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG, Fugazzola L. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol 2010; 72:702-8; PMID:20447069; http://dx.doi.org/10.1111/j.1365-2265.2009.03699.x
   PubMed Web of Science ®Google Scholar
• Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor kappaB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab 2014; 99:E1436-44; PMID:24758177; http://dx.doi.org/10.1210/jc.2013-3636
   PubMedGoogle Scholar
• Fang W, Ye L, Shen L, Cai J, Huang F, Wei Q, Fei X, Chen X, Guan H, Wang W et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 2014; 35:1780-7; PMID:24608042; http://dx.doi.org/10.1093/carcin/bgu060
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrine-related cancer 2009; 16:1299-311; PMID:19755523; http://dx.doi.org/10.1677/ERC-08-0337
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun DX, Teng XY, Xu WX, Meng XP, Wang BS. Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma. Endocrine Pathol 2012; 23:247-53; PMID:23070788; http://dx.doi.org/10.1007/s12022-012-9223-x
   PubMed Web of Science ®Google Scholar
• Chung SY, Park ES, Park SY, Song JY, Ryu HS. CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma. Head & neck 2014; 36:1005-12; PMID:23784811; http://dx.doi.org/10.1002/hed.23404
   PubMed Web of Science ®Google Scholar
• Liu Z, Yang L, Teng X, Zhang H, Guan H. The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma. J Surg Res 2014; 191:379-88; PMID:24814201; http://dx.doi.org/10.1016/j.jss.2014.04.016
   PubMed Web of Science ®Google Scholar
• Zeng W, Chang H, Ma M, Li Y. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol 2014; 97:184-90; PMID:24984269; http://dx.doi.org/10.1016/j.yexmp.2014.06.012
   PubMed Web of Science ®Google Scholar
• Passaro C, Borriello F, Vastolo V, Somma SD, Scamardella E, Gigantino V, Franco R, Marone G, Portella G. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget 2015; 7(2):1500-15; PMID:26625205; http://dx.doi.org/10.18632/oncotarget.6430
   Web of Science ®Google Scholar
• Loffredo S, Staiano RI, Granata F, Genovese A, Marone G. Immune cells as a source and target of angiogenic and lymphangiogenic factors. In: Marone G, Granata F, eds. Angiogenesis, Lymphangiogenesis and Clinical Implications Chem Immunol Allergy. Basel: Karger 2014; 99:15-36; PMID:24217601; http://dx.doi.org/10.1159/000353316
   Google Scholar
• Detoraki A, Staiano RI, Granata F, Giannattasio G, Prevete N, de Paulis A, Ribatti D, Genovese A, Triggiani M, Marone G. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol 2009; 123:1142-9, 9 e1-5; PMID:19275959; http://dx.doi.org/10.1016/j.jaci.2009.01.044
   PubMed Web of Science ®Google Scholar
• Granata F, Frattini A, Loffredo S, Staiano RI, Petraroli A, Ribatti D, Oslund R, Gelb MH, Lambeau G, Marone G et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol 2010; 184:5232-41; PMID:20357262; http://dx.doi.org/10.4049/jimmunol.0902501
   PubMed Web of Science ®Google Scholar
• Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, Cantelmo AR, Franzi F, Capella C, Ferlazzo G et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 2013; 15:133-42; PMID:23441128; http://dx.doi.org/10.1593/neo.121758
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64:5535-8; PMID:15313886; http://dx.doi.org/10.1158/0008-5472.CAN-04-1272
   PubMed Web of Science ®Google Scholar
• Nissim Ben Efraim AH, Levi-Schaffer F. Roles of Eosinophils in the Modulation of Angiogenesis. In: Marone G, Granata F, eds. Angiogenesis, Lymphangiogenesis and Clinical Implications. Chem Immunol Allergy. Basel: Karger, 2014:138-54.
   Google Scholar
• Shiraishi J, Koyama H, Seki M, Hatayama M, Naka M, Kurajoh M, Okazaki H, Shoji T, Moriwaki Y, Yamamoto T et al. Anaplastic thyroid carcinoma accompanied by uncontrollable eosinophilia. Internal medicine 2015; 54:611-6; PMID:25786451; http://dx.doi.org/10.2169/internalmedicine.54.3446
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475:226-30; PMID:21753853; http://dx.doi.org/10.1038/nature10169
   PubMed Web of Science ®Google Scholar
• Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-31; PMID:18633355; http://dx.doi.org/10.1038/nrc2444
   PubMed Web of Science ®Google Scholar
• De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer cell 2005; 8:211-26; PMID:16169466; http://dx.doi.org/10.1016/j.ccr.2005.08.002
   PubMed Web of Science ®Google Scholar
• de Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006; 177:7322-31; PMID:17082651; http://dx.doi.org/10.4049/jimmunol.177.10.7322
   PubMed Web of Science ®Google Scholar
• Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17:320-9; PMID:21383745; http://dx.doi.org/10.1038/nm.2328
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (New York, NY 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013; 228:1404-12; PMID:23065796; http://dx.doi.org/10.1002/jcp.24260
   PubMed Web of Science ®Google Scholar
• Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-related cancer 2008; 15:1069-74; PMID:18719091; http://dx.doi.org/10.1677/ERC-08-0036
   PubMed Web of Science ®Google Scholar
• Kim S, Cho SW, Min HS, Kim KM, Yeom GJ, Kim EY, Lee KE, Yun YG, Park do J, Park YJ. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab 2013; 28:192-8; PMID:24396678; http://dx.doi.org/10.3803/EnM.2013.28.3.192
   PubMedGoogle Scholar
• Jung KY, Cho SW, Kim YA, Kim D, Oh BC, Park do J, Park YJ. Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. J Pathol Transl Med 2015; 49:318-24; PMID:26081823; http://dx.doi.org/10.4132/jptm.2015.06.01
   PubMedGoogle Scholar
• Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M, Dupuy C. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One 2011; 6:e22567; PMID:21811634; http://dx.doi.org/10.1371/journal.pone.0022567
   PubMed Web of Science ®Google Scholar
• Chang WC, Chen JY, Lee CH, Yang AH. Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma: correlation with M2 macrophage differentiation and lymphatic invasion. Thyroid 2013; 23:720-6; PMID:23186064; http://dx.doi.org/10.1089/thy.2012.0261
   PubMed Web of Science ®Google Scholar
• Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC, Chen X, Wang WQ, Li XY, Xiao JC et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012; 22:905-10; PMID:22870901; http://dx.doi.org/10.1089/thy.2011.0452
   PubMed Web of Science ®Google Scholar
• Dudek AM, Martin S, Garg AD, Agostinis P. Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol 2013; 4:438; PMID:24376443; http://dx.doi.org/10.3389/fimmu.2013.00438
   PubMed Web of Science ®Google Scholar
• Hilly O, Koren R, Raz R, Rath-Wolfson L, Mizrachi A, Hamzany Y, Bachar G, Shpitzer T. The role of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma. Am J Clin Pathol 2013; 139:87-92; PMID:23270903; http://dx.doi.org/10.1309/AJCPAKYDO56NKMYZ
   PubMed Web of Science ®Google Scholar
• Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC, Sozzani S, Allavena P, Mantovani A, Ruco LP. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 2000; 156:831-7; PMID:10702399; http://dx.doi.org/10.1016/S0002-9440(10)64951-6
   PubMed Web of Science ®Google Scholar
• Tsuge K, Takeda H, Kawada S, Maeda K, Yamakawa M. Characterization of dendritic cells in differentiated thyroid cancer. J Pathol 2005; 205:565-76; PMID:15714595; http://dx.doi.org/10.1002/path.1731
   PubMed Web of Science ®Google Scholar
• Ugolini C, Basolo F, Proietti A, Vitti P, Elisei R, Miccoli P, Toniolo A. Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid 2007; 17:389-93; PMID:17542668; http://dx.doi.org/10.1089/thy.2006.0306
   PubMed Web of Science ®Google Scholar
• Marone G, Galli SJ, Kitamura Y. Probing the roles of mast cells and basophils in natural and acquired immunity, physiology and disease. Trends Immunol 2002; 23:425-7; PMID:12200056; http://dx.doi.org/10.1016/S1471-4906(02)02274-3
   PubMedGoogle Scholar
• Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol 2015; 778:146-51; PMID:25941082; http://dx.doi.org/10.1016/j.ejphar.2015.03.088.
   PubMed Web of Science ®Google Scholar
• Proietti A, Ugolini C, Melillo RM, Crisman G, Elisei R, Santoro M, Minuto M, Vitti P, Miccoli P, Basolo F. Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid 2011; 21:1209-15; PMID:22007938; http://dx.doi.org/10.1089/thy.2011.0059
   PubMed Web of Science ®Google Scholar
• Detoraki A, Granata F, Staibano S, Rossi FW, Marone G, Genovese A. Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 2010; 65:946-58; PMID:20415716; http://dx.doi.org/10.1111/j.1398-9995.2010.02372.x
   PubMed Web of Science ®Google Scholar
• Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. Semin Immunopathol 2013; 35:377-94; PMID:23553214; http://dx.doi.org/10.1007/s00281-013-0374-8
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009; 16:183-94; PMID:19732719; http://dx.doi.org/10.1016/j.ccr.2009.06.017
   PubMed Web of Science ®Google Scholar
• Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200:197-203; PMID:20122680; http://dx.doi.org/10.1016/j.amjsurg.2009.08.041
   PubMed Web of Science ®Google Scholar
• Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013; 107:493-7; PMID:22996403; http://dx.doi.org/10.1002/jso.23270
   PubMed Web of Science ®Google Scholar
• Seretis C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E, Dimitrakopoulos G. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg 2013; 205:691-6; PMID:23388425; http://dx.doi.org/10.1016/j.amjsurg.2012.08.006
   PubMed Web of Science ®Google Scholar
• Lang BH, Ng CP, Au KB, Wong KP, Wong KK, Wan KY. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma? World journal of surgery 2014; 38:2605-12; PMID:24809487; http://dx.doi.org/10.1007/s00268-014-2630-z
   PubMed Web of Science ®Google Scholar
• Cho JS, Park MH, Ryu YJ, Yoon JH. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer. Annals of surgical treatment and research 2015; 88:187-92; PMID:25844352; http://dx.doi.org/10.4174/astr.2015.88.4.187
   PubMed Web of Science ®Google Scholar
• Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-75; PMID:21061430; http://dx.doi.org/10.1002/eji.201040895
   PubMed Web of Science ®Google Scholar
• Suzuki S, Shibata M, Gonda K, Kanke Y, Ashizawa M, Ujiie D, Suzushino S, Nakano K, Fukushima T, Sakurai K et al. Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol Clin Oncol 2013; 1:959-64; PMID:24649277; http://dx.doi.org/10.3892/mco.2013.170
   PubMedGoogle Scholar
• Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J, Ward LS. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol 2012; 77:918-25; PMID:22738343; http://dx.doi.org/10.1111/j.1365-2265.2012.04482.x
   PubMed Web of Science ®Google Scholar
• Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319:47-65; PMID:24965257; http://dx.doi.org/10.1111/nyas.12469
   PubMed Web of Science ®Google Scholar
• Wang F, Tian Z, Wei H. Genomic expression profiling of NK cells in health and disease. Eur J Immunol 2015; 45:661-78; PMID:25476835; http://dx.doi.org/10.1002/eji.201444998
   PubMed Web of Science ®Google Scholar
• Gogali F, Paterakis G, Rassidakis GZ, Kaltsas G, Liakou CI, Gousis P, Neonakis E, Manoussakis MN, Liapi C. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. J Clin Endocrinol Metab 2012; 97:1474-82; PMID:22399513; http://dx.doi.org/10.1210/jc.2011-1838
   PubMed Web of Science ®Google Scholar
• Gogali F, Paterakis G, Rassidakis GZ, Liakou CI, Liapi C. CD3(−)CD16(−)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. Thyroid 2013; 23:1561-8; PMID:23721357; http://dx.doi.org/10.1089/thy.2012.0560
   PubMed Web of Science ®Google Scholar
• Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminskyy VO, Juhlin CC, Hoog A, Bodin I, Svjatoha V et al. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. Clin Cancer Res 2014; 20:5733-44; PMID:25212604; http://dx.doi.org/10.1158/1078-0432.CCR-14-0291
   PubMed Web of Science ®Google Scholar
• Parhar RS, Zou M, Al-Mohanna FA, Baitei EY, Assiri AM, Meyer BF, Shi Y. IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model. Lab Invest 2016; 96:89-97; PMID:26501867; http://dx.doi.org/10.1038/labinvest.2015.126
   PubMed Web of Science ®Google Scholar
• Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front Immunol 2014; 5:543; PMID:25389427; http://dx.doi.org/10.3389/fimmu.2014.00543
   PubMed Web of Science ®Google Scholar
• Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491-503; PMID:21383056; http://dx.doi.org/10.1084/jem.20100269
   PubMed Web of Science ®Google Scholar
• Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015; 517:293-301; PMID:25592534; http://dx.doi.org/10.1038/nature14189
   PubMed Web of Science ®Google Scholar
• Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010; 11:1030-8; PMID:20935648; http://dx.doi.org/10.1038/ni.1947
   PubMed Web of Science ®Google Scholar
• Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20:323-70; PMID:11861606; http://dx.doi.org/10.1146/annurev.immunol.20.100201.131730
   PubMed Web of Science ®Google Scholar
• Cunha LL, Marcello MA, Nonogaki S, Morari EC, Soares FA, Vassallo J, Ward LS. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. Clin Endocrinol 2015; 83:246-53; PMID:25130519; http://dx.doi.org/10.1111/cen.12586
   PubMed Web of Science ®Google Scholar
• Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014; 24:1385-93; PMID:24955518; http://dx.doi.org/10.1089/thy.2014.0134
   PubMed Web of Science ®Google Scholar
• Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 2010; 21:3-10; PMID:20005150; http://dx.doi.org/10.1016/j.cytogfr.2009.11.002
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918
   PubMed Web of Science ®Google Scholar
• Imam S, Paparodis R, Sharma D, Jaume JC. Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. Endocrine-related cancer 2014; 21:505-16; PMID:24623740; http://dx.doi.org/10.1530/ERC-13-0436
   PubMed Web of Science ®Google Scholar
• Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM. Treg(s) in Cancer: Friends or Foe? J Cell Physiol 2015; 230:2598-605; PMID:25913194; http://dx.doi.org/10.1002/jcp.25016
   PubMed Web of Science ®Google Scholar
• French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Jr, Klopper JP, Haugen BR. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 2012; 97:E934-43; PMID:22466343; http://dx.doi.org/10.1210/jc.2011-3428
   PubMed Web of Science ®Google Scholar
• French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2325-33; PMID:20207826; http://dx.doi.org/10.1210/jc.2009-2564
   PubMed Web of Science ®Google Scholar
• Ryu HS, Park YS, Park HJ, Chung YR, Yom CK, Ahn SH, Park YJ, Park SH, Park SY. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma. Thyroid 2014; 24:1232-40; PMID:24742251; http://dx.doi.org/10.1089/thy.2013.0423
   PubMed Web of Science ®Google Scholar
• Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92; PMID:23778140; http://dx.doi.org/10.1172/JCI67428
   PubMed Web of Science ®Google Scholar
• Kaplan MH, Hufford MM, Olson MR. The development and in vivo function of T helper 9 cells. Nat Rev Immunol 2015; 15:295-307; PMID:25848755; http://dx.doi.org/10.1038/nri3824
   PubMed Web of Science ®Google Scholar
• Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rebe C, Derangere V, Ryffel B et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 2014; 15:758-66; PMID:24973819; http://dx.doi.org/10.1038/ni.2925
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A. Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front Endocrinol 2015; 6:176; PMID:26635725; http://dx.doi.org/10.3389/fendo.2015.00176
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70:2235-44; PMID:20215499; http://dx.doi.org/10.1158/0008-5472.CAN-09-2335
   PubMed Web of Science ®Google Scholar
• Wright KT, Giardina C, Vella AT. Therapeutic targeting of the inflammome. Biochem Pharmacol 2014; 92:184-91; PMID:25204592; http://dx.doi.org/10.1016/j.bcp.2014.08.027
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 2015; 15:45-56; PMID:25534622; http://dx.doi.org/10.1038/nri3790
   PubMed Web of Science ®Google Scholar